<div><div></div><div><span><p><span>Enanta Pharmaceuticals Inc reported third-quarter fiscal 2026 results with revenue of $17.16M and a net loss that narrowed versus the year-ago quarter, reflecting stronger royalty receipts and continued investment in its RSV and immunology programs.</span></p><p><strong><span>Financial Highlights</span></strong></p><ul><li><span>Revenue was $17.159M for Q3 2026, compared with $14.926M in the year-ago quarter; YoY change 15.0%.</span></li><li><span>Net income (loss) was a loss of $13.091M for Q3 2026, compared with a loss of $22.644M in the year-ago quarter; improvement year over year.</span></li><li><span>Diluted earnings per share was $(0.45) for Q3 2026, compared with $(1.06) per share in the year-ago quarter; improvement year over year.</span></li></ul><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Royalty revenue momentum: Royalty revenue rose year over year, driven by higher MAVYRET/MAVIRET sales and a U.S. acute HCV label expansion; revenue was $17.2M in the quarter and $35.8M year-to-date.</span></li><li><span>RSV program progress: Zelicapavir reported positive Phase 2b topline results in high‑risk adults and positive pediatric topline results; the company is planning a pivotal study and engaging with the FDA.</span></li><li><span>Immunology pipeline advances: EDP‑978 entered Phase 1 single- and multiple-ascending dose dosing; STAT6 candidate EPS‑3903 is on track for an IND in H2 2026; selection of an MRGPRX2 preclinical candidate is planned for H2 2026.</span></li><li><span>R&amp;D spending shift: Overall R&amp;D decreased due to RSV trial timing while investments increased in immunology and early discovery to reflect pipeline prioritization.</span></li><li><span>Liquidity outlook: Cash and marketable securities of $227M provide a development runway into fiscal 2029 per management guidance.</span></li></ul><p><span>Original SEC Filing: </span>ENANTA PHARMACEUTICALS INC [ ENTA ] - 10-Q - May. 13, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

ENTA

<p>Enanta Pharmaceuticals Inc reported Q3 2026 revenue of $17.16M, a 15% increase from $14.93M in the previous year. The net loss narrowed to $13.09M from $22.64M, with diluted EPS improving to $(0.45) from $(1.06). Royalty revenue rose due to higher MAVYRET/MAVIRET sales. The RSV program showed positive Phase 2b results, and the immunology pipeline advanced with EDP-978 entering Phase 1. Cash and marketable securities stand at $227M, supporting development through fiscal 2029.</p>

TradingView

Enanta Pharma

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

iShares US Pharma

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

iShares Biotechnology ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

ALPS Medical Breakthrough

ENANTA PHARMACEUTICALS INC 3Q 2026: Revenue $17.16M, EPS $(0.45) — 10-Q Summary